Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mrinal M. Gounder, Michelle R. Mahoney, Brian Andrew Van Tine, Vinod Ravi, Steven Attia, Hari Anant Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert Martin Conry, Sujana Movva, Michael J. Pishvaian, Jeffrey Crawford, Tarek Sabagh, Robert G. Maki, William D. Tap, Robert A Lefkowitz, Narasimhan P Agaram, John Joseph Wright, Amylou C. Dueck, Gary K. Schwartz
Institutions: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Mayo Clinic in Florida, Yale Cancer Center, Princess Margaret Cancer Centre, University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, Fox Chase Cancer Center, Georgetown University Medical Center, Duke Medical Center, Northwell Health, Cold Spring Harbor Laboratory, National Institutes of Health, National Cancer Institute, Mayo Clinic in Arizona, Columbia University Irving Medical Center
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891373127